Stay updated with breaking news from Nasdaq Jspr. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Jasper Therapeutics, Inc. (NASDAQ:JSPR – Get Rating) saw a significant decrease in short interest in the month of March. As of March 31st, there was short interest totalling 130,700 shares, a decrease of 30.6% from the March 15th total of 188,400 shares. Based on an average trading volume of 90,300 shares, the short-interest ratio is […]
REDWOOD CITY, Calif., March 25, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on...
Jasper Therapeutics Inc (NASDAQ:JSPR – Get Rating) – Equities research analysts at Oppenheimer lowered their FY2022 EPS estimates for Jasper Therapeutics in a research report issued to clients and investors on Monday, March 21st. Oppenheimer analyst J. Olson now expects that the company will earn ($1.18) per share for the year, down from their previous […]
JSP191 is well tolerated with no treatment-related severe adverse events in 17 subjects with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)...